Anthrax vaccine - Harvard University/Soligenix

Drug Profile

Anthrax vaccine - Harvard University/Soligenix

Alternative Names: DNI-rPA; SGX-204; VeloThrax

Latest Information Update: 19 Aug 2014

Price : $50

At a glance

  • Originator Harvard University
  • Developer Soligenix
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Anthrax

Most Recent Events

  • 19 Aug 2014 Anthrax vaccine - Harvard University/Soligenix is available for licensing in World as of 19 Aug 2014.
  • 07 Aug 2014 Preclinical development is ongoing in USA
  • 15 Jan 2014 Preclinical pharmacodynamics data on thermostable version of anthrax vaccine released by Soligenix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top